Stiripentol

Stiripentol API (CAS No: 49763-96-4) is carefully produced at Amber Lifesciences Pvt. Ltd. in GMP-certified and ISO 9001:2015 compliant manufacturing facilities, ensuring exceptional purity, batch-to-batch consistency, and adherence to global regulatory standards. Each production batch is accompanied by a comprehensive Certificate of Analysis (COA) and Material Safety Data Sheet (MSDS), meeting USP/EP pharmacopeial specifications.

Stiripentol is an anticonvulsant medication used as an adjunctive therapy in the treatment of severe myoclonic epilepsy in infancy (Dravet syndrome). It enhances gamma-aminobutyric acid (GABA) neurotransmission and inhibits the metabolism of other antiepileptic drugs, thereby increasing their effectiveness. Our API undergoes rigorous quality control and validated manufacturing processes to ensure high efficacy and safety in pharmaceutical formulations.

Amber Lifesciences supports pharmaceutical manufacturers, contract developers, exporters, shippers, and formulation partners across Asia, Europe, the Middle East, and LATAM regions by offering reliable supply chains, expert technical support, and comprehensive regulatory documentation to facilitate smooth product registration and quick market entry.

Storage & Transportation

Classified as non-Dangerous Goods. Store at controlled room temperature (20°C to 25°C / 68°F to 77°F), away from moisture, light, and heat. Handle according to standard pharmaceutical transport and storage guidelines.